SOLICITATION NOTICE
D -- Etiologic Factors for Prostate Cancer Progression in the PLCO Cancer Screening Trial
- Notice Date
- 8/5/2011
- Notice Type
- Presolicitation
- NAICS
- 518210
— Data Processing, Hosting, and Related Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110135-MW
- Archive Date
- 9/3/2011
- Point of Contact
- Melissa R. Ward, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
wardmr@mail.nih.gov, cr214i@nih.gov
(wardmr@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6072, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG), plans to procure on a sole source basis with Westat, 1600 Research Blvd., Rockville, MD 20850 for services in support of etiologic factors for prostate cancer progression in the Prostate, Lung, Colorectal, & Ovarian (PLCO) cancer screening trial. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 518210 and the business size standard in $25M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of performance shall be for twelve months from September 1, 2011 through August 31, 2012 or date of award, whichever is later. The PLCO Cancer Screening Trial, sponsored by the NCI, is a multicenter randomized trial that is evaluating the effectiveness of prostate, lung, colorectal, and ovarian cancer screening modalities on disease-specific mortality. PLCO Trial infrastructure is in place for long-term mortality follow-up, however, clinical follow-up is limited to one-year post-diagnosis, which identifies the initial course of treatment used for men diagnosed with prostate cancer, including both surgical (providing pathological stage and grade) and non-surgical options. Current contracts are in place with nine of the ten PLCO centers to collect additional follow-up data beyond the first-year post-diagnosis to capture all clinically relevant data related to prostate cancer recurrence and progression. The purpose of this procurement is to code and enter all the interview and medical record abstraction data collected across all nine PLCO centers. The contractor shall revise the codebooks and entry programs for the questionnaires and abstraction forms, develop monitoring reports, review and code all forms, complete data entry for all surveys and abstraction forms, and create a tracking spreadsheet for tissue collection. Westat is the sole agency that has been providing infrastructure support for the PLCO Trial over the course of the last 17 years. Westat has done all of the data coding, data entry, and data monitoring for the PLCO Trial. Significant investment has been made in Westat to establish a data coding and entry system during the pilot phase of this prostate cancer progression project and Westat has provided essential infrastructure support to keep the data collection at nine screening centers on track through its monitoring and receipt systems. The data collection phase is now nearing its end, and all the data that has been receipted by Westat must be coded and entered into their system. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 19, 2011. No electronic capability statements will be accepted (i.e. email or fax). An original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Ward, Contract Specialist, at wardmr@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110135-MW on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110135-MW/listing.html)
- Record
- SN02524222-W 20110807/110805235504-02c21a784165cb20d1329242cc2efa60 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |